Abdullatif Al-Khal

List of Publications by Year
in descending order

71 papers	5,139 citations	159358 30 h-index	128067 60 g-index
89 all docs	89 docs citations	89 times ranked	4629 citing authors

#	Article	IF	Citations
1	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. New England Journal of Medicine, 2021, 385, e83.	13.9	675
2	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. New England Journal of Medicine, 2022, 387, 21-34.	13.9	368
3	Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. New England Journal of Medicine, 2022, 386, 1288-1290.	13.9	356
4	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nature Medicine, 2021, 27, 2136-2143.	15.2	346
5	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nature Medicine, 2021, 27, 1614-1621.	15.2	337
6	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. New England Journal of Medicine, 2022, 386, 1804-1816.	13.9	311
7	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nature Communications, 2022, 13, .	5.8	188
8	Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. Clinical Infectious Diseases, 2021, 73, e1830-e1840.	2.9	154
9	SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine, 2021, 35, 100861.	3.2	153
10	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. JAMA - Journal of the American Medical Association, 2021, 326, 1930.	3.8	140
11	COVIDâ€19 vaccine hesitancy and attitudes in Qatar: A national crossâ€sectional survey of a migrantâ€majority population. Influenza and Other Respiratory Viruses, 2021, 15, 361-370.	1.5	119
12	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Scientific Reports, 2021, 11, 6233.	1.6	117
13	Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant. Clinical Infectious Diseases, 2022, 75, e361-e367.	2.9	83
14	Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 Februaryâ€“18 April 2020. BMJ Open, 2020, 10, e040428.	0.8	82
15	Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. JAMA Internal Medicine, 2022, 182, 197.	2.6	81
16	SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. IScience, 2021, 24, 102646.	1.9	79
17	Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. Emerging Infectious Diseases, 2021, 27, 1343-1352.	2.0	74
18	Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. International Journal of Infectious Diseases, 2021, 110, 353-358.	1.5	74

#	Article	IF	Citations
19	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. Journal of Global Health, 2021, 11, 05005.	1.2	71
20	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. Journal of Travel Medicine, 2021, 28, .	1.4	69
21	Within-Host Diversity of SARS-CoV-2 in COVID-19 Patients With Variable Disease Severities. Frontiers in Cellular and Infection Microbiology, 2020, 10, 575613.	1.8	67
22	Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar. International Journal of Infectious Diseases, 2021, 112, 52-54.	1.5	59
23	SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. Open Forum Infectious Diseases, 2021, 8, ofab221.	0.4	58
24	One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar. Frontiers in Cellular and Infection Microbiology, 2021, 11, 768883.	1.8	56
25	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. PLoS Medicine, 2021, 18, e1003879.	3.9	54
26	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. Nature Communications, 2022, 13, 532.	5.8	53
27	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. Scientific Reports, 2021, 11, 18182.	1.6	49
28	SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women. Journal of Clinical Investigation, 2021, 131, .	3.9	49
29	COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar. Journal of Global Health, 0, 12, .	1.2	48
30	The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study. BMC Infectious Diseases, 2020, 20, 777.	1.3	41
31	Antibiotic prescription patterns for upper respiratory tract infections in the outpatient Qatari population in the private sector. International Journal of Infectious Diseases, 2017, 55, 20-23.	1.5	39
32	Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. Clinical Infectious Diseases, 2022, 75, e1188-e1191.	2.9	38
33	Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report. Journal of Medical Virology, 2021, 93, 1678-1686.	2.5	37
34	Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar. JAMA - Journal of the American Medical Association, 2021, 326, 185.	3.8	37
35	Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections. Journal of Travel Medicine, 2022, 29, .	1.4	37
36	Epidemiology and clinical outcomes of viral central nervous system infections. International Journal of Infectious Diseases, 2018, 73, 85-90.	1.5	33

#	Article	IF	Citations
37	Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. Nature Communications, 2022, 13, 946.	5.8	30
38	Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. BMJ Innovations, 2021, 7, 327-336.	1.0	27
39	Job satisfaction and stress among healthcare workers in public hospitals in Qatar. Archives of Environmental and Occupational Health, 2020, 75, 10-17.	0.7	22
40	Molecular characterization of clinical carbapenem-resistant Enterobacterales from Qatar. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1779-1785.	1.3	22
41	Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. Infection, Genetics and Evolution, 2021, 88, 104684.	1.0	22
42	Epidemiology of respiratory infections among adults in Qatar (2012-2017). PLoS ONE, 2019, 14, e0218097.	1.1	19
43	Molecular epidemiology of influenza, RSV, and other respiratory infections among children in Qatar: A six years report (2012â€“2017). International Journal of Infectious Diseases, 2020, 95, 133-141.	1.5	19
44	Performance evaluation of five ELISA kits for detecting anti-SARS-COV-2 IgG antibodies. International Journal of Infectious Diseases, 2021, 102, 181-187.	1.5	19
45	Clinician-educators in emerging graduate medical education systems: description, roles and perceptions. Postgraduate Medical Journal, 2016, 92, 14-20.	0.9	14
46	Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. Scientific Reports, 2021, 11, 11837.	1.6	14
47	Qatar's response to COVID-19 pandemic. Heart Views, 2020, 21, 129.	0.1	14
48	Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar. Clinical Therapeutics, 2016, 38, 1158-1173.	1.1	11
49	Implementing and tailoring a western-developed communication skills training program for graduate medical trainees in Qatar. International Journal of Medical Education, 2017, 8, 16-18.	0.6	11
50	Cerebral schistosomiasis: Case series from Qatar. International Journal of Infectious Diseases, 2019, 86, 167-170.	1.5	11
51	Burnout and sources of stress among medical residents at Hamad Medical Corporation, Qatar. Eastern Mediterranean Health Journal, 2017, 23, 40-46.	0.3	10
52	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatarâ€™s experience. Journal of Global Health, 2022, 12, 05004.	1.2	7
53	Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study. PLoS ONE, 2022, 17, e0267884.	1.1	7
54	Reporting of RT-PCR cycle threshold (Ct) values during the first wave of COVID-19 in Qatar improved result interpretation in clinical and public health settings. Journal of Medical Microbiology, 2022, 71, .	0.7	7

#	Article	IF	Citations
55	Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference. Clinical Therapeutics, 2015, 37, 2798-2810.	1.1	6
56	Clinical characteristics, microbiology, and outcomes of infective endocarditis in Qatar. Qatar Medical Journal, 2020, 2020, 24.	0.2	6
57	Middle East respiratory syndrome coronavirus infection profile in Qatar: An 8-year experience. IDCases, 2021, 24, e01161.	0.4	5
58	First characterisation of antimicrobial susceptibility and resistance of Neisseria gonorrhoeae isolates in Qatar, 2017â€“2020. PLoS ONE, 2022, 17, e0264737.	1.1	5
59	Drug-resistant tuberculosis: an experience from Qatar. Libyan Journal of Medicine, 2020, 15, 1744351.	0.8	4
60	Molecular characteristics of Neisseria meningitidis in Qatar. Scientific Reports, 2021, 11, 4812.	1.6	2
61	Satisfaction with a 2-day communication skills course culturally tailored for medical specialists in Qatar. Journal of Family and Community Medicine, 2017, 24, 122-127.	0.5	2
62	Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2. PLoS ONE, 2022, 17, e0262897.	1.1	1
63	Viral Infections of the Central Nervous System in Qatar: Epidemiology, Pathogenesis and Clinical Outcomes. Open Forum Infectious Diseases, 2017, 4, S305-S305.	0.4	0
64	739. Middle East Respiratory Syndrome Coronavirus Infection Profile in Qatar: A 7-Year Retrospective Study. Open Forum Infectious Diseases, 2018, 5, S265-S265.	0.4	0
65	630. Clinical and Molecular Characteristics of Carbapenem-Resistant Enterobacteriaceae in Qatar: A Retrospective and Prospective Observational Study. Open Forum Infectious Diseases, 2019, 6, S292-S292.	0.4	0
66	163. Infective Endocarditis in Qatar: Risk Factors, Clinical Characteristics, Microbiology, and Outcomes. Open Forum Infectious Diseases, 2019, 6, S106-S107.	0.4	0
67	Viral infections of the central nervous system in Qatar: epidemiology, pathogenesis and clinical outcomes. Journal of Infection in Developing Countries, 2018, 12, 29S.	0.5	0
68	Early laboratory markers may reflect the severity of pyogenic liver abscess infection: Retrospective cohort study. Access Microbiology, 2020, 2, .	0.2	0
69	Clinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study. Cureus, 2022, 14, e23263.	0.2	0
70	508. Title Favipiravir for the Treatment of Coronavirus Disease 2019; A Propensity Score Matched Cohort Study. Open Forum Infectious Diseases, 2021, 8, S356-S356.	0.4	0
71	1247. Molecular Epidemiology of Multi-drug Resistant Klebsiella pneumoniae and K. quasipneumoniae in Qatar. Open Forum Infectious Diseases, 2021, 8, S712-S712.	0.4	0